Letter of Intent: 30 days before the chosen submission deadline

Submission Deadlines: December 10, 2020 – April 9, 2021 – August 10, 2021

Budget: up to 160000,00 EUR

Objectives: The objectives of this funding opportunity announcement (FOA) are to support basic, translational and clinical research to (1) advance the understanding of underlying mechanisms of drug action; (2) discover and develop novel therapeutics; (3) enhance the usage of existing drugs or drug repurposing for safer and more effective medications in pregnant and lactating women and children. The overall goal is to improve safe and effective precision therapeutics for pregnant and lactating women and for neonates and children.

Scope: Applications should address research topics relevant to NICHD’s strategic plan Theme Five on advancing safe and effective therapeutics for pregnant and lactating women and children which is outlined in the link: NICHD Strategic Plan.

Proposed research activities should also align with the OPPTB’s research priorities to expand the knowledge in pharmacokinetics, pharmacodynamics, pharmacogenomics, biomarkers, new drug development and drug repurposing for the treatment of maternal and pediatric diseases. Examples of research priorities can be found at the link: OPPTB Research Priorities. Applicants may also consider research priorities identified in the Best Pharmaceuticals for Children Act (BPCA) Priority List of Needs in Pediatric Therapeutics (BPCA Priority List) as well as in the PRGLAC Recommendations. Applicants involved in pediatric drug development may consult with experts in Pediatric Drug Development Trial Design. Knowledge deficits in maternal and pediatric pharmacology may require interaction between disciplines in which case a multiple integrated and interactive research team to address interrelated research areas is encouraged.

For the purpose of this FOA, maternal and pediatric therapeutics is defined to encompass: Therapeutic treatment of obstetric and breastfeeding conditions; Physiological changes that occur in a woman’s body during pregnancy, the post-partum period, and during lactation that impact the distribution or effects of administered therapeutics;
Passage of drug from mother to fetus during pregnancy and to child during breastfeeding, including the effects of those drugs on the fetus or child; Therapeutic treatment of pediatric disease, particularly where there are unique pediatric conditions or pharmacodynamic differences from adult disease; Physiological changes that occur across the entire spectrum of pediatric development from birth through adolescence that impact the distribution or effects of administered therapeutics.

---

The Michael J. Fox Foundation for Parkinson Research
The Edmond J. Safra Fellowship in Movement Disorders

**Objective:** Movement disorder specialists (neurologists with subspecialty training in Parkinson's disease and other movement disorders) serve as an important bridge between scientific advances in the lab and positive patient outcomes in the care setting.

---

**Deadlines:** December 10, 2020

**Budget:** up to 160000.00 EUR

While the demand for movement disorder specialists is increasing, not enough neurologists are receiving this vital training. To address this unmet need, The Michael J. Fox Foundation (MJFF), in collaboration with longtime partner the Edmond J. Safra Foundation, introduced The Edmond J. Safra Fellowship in Movement Disorders. By funding academic centers to train new movement disorder clinician-researchers, this program aims to develop a network of highly trained specialists to be the next generation of leaders in Parkinson's research and clinical care.

---

**The Michael J. Fox Foundation for Parkinson Research**
**ASAP Collaborative Research Network: Circuitry and Brain-body Interactions**

**Pre-Proposal Deadline:** December 11, 2020, 5 p.m. ET

**Budget:** up to 9000000.00 EUR for three-year grants (requests should not exceed $3 million per year)

This program solely funds basic research aimed at understanding the 1) structure and function of the nervous system (and related physiological systems) and 2) disease mechanisms that contribute to Parkinson's disease. Research can involve studies performed in vitro, in animals or in humans.

For this priority area, ASAP is interested in understanding its dynamics during the prodromal period and how it is altered during the progression to overt disease. This RFA is open to international organizations including public and private non-profit groups, agencies of the U.S. federal government, and for-profit entities. Applications must be submitted by multidisciplinary, multi-institutional research teams consisting of three to five investigators.

ASAP is leveraging The Michael J. Fox Foundation's grant administration and
grantmaking infrastructure to receive applications, administer the review process and make grant awards to projects selected for funding. As such, applicants may hear from ASAP staff or Foundation staff pertaining to their submissions.

**Objective:** The ASAP Collaborative Research Network, a program of the Aligning Science Across Parkinson’s (ASAP) initiative being implemented through The Michael J. Fox Foundation, seeks to support multidisciplinary, multi-institutional research teams to address key knowledge gaps in the basic mechanisms that contribute to Parkinson’s development and progression.

Applications should focus on studies that achieve one or more of the following:
- *In vivo* imaging of brain neurofilaments of 4R tau and alpha-synuclein pathology that could be useful as biomarkers of the presence of disease and disease progression and as pharmacodynamic tools for drug development for tauopathies or synucleinopathies
- Structure- and ligand-based drug design approaches that use state-of-art computational methods based on the high resolution Cryo-EM structures of disease-relevant tau and alpha-synuclein fibrils and existing Structure Activity Relationship (SAR) on known tau PET ligands or alpha-synuclein PET ligands that are in development. Particular interest is in projects to develop alpha-synuclein and tau tracers in parallel.

**The Michael J. Fox Foundation for Parkinson Research**
**PIPETTE: 4R Tau and Alpha-Synuclein PET Tracer Development**

Pre-Proposal Deadline: October 22, 2020, 5 p.m. US ET

Total available budget: 1000000,00 EUR

The partnership’s goal is to accelerate the development of novel 4R tau and alpha-synuclein PET tracers for primary non-Alzheimer’s tauopathies, Parkinson’s disease, Lewy body dementia, frontotemporal dementia, and other neurodegenerative diseases. As a collaborative effort of leading non-profit organizations, the PIPETTE Consortium seeks to pool ideas, expertise, and resources to enable improved diagnosis and treatment of multiple disorders.

**European Research Council (ERC) CALL Calendar 2021**

**Starting Grants** | ERC-2021-StG
Open: 12-01-2021
Deadline: 09-03-2021

**Consolidator Grants** | ERC-2021-CoG
Open: 21-01-2021
Deadline: 20-04-2021

**Advanced Grants** | ERC-2021-AdG
Open: 20-05-2021
Deadline: 31-08-2021

**Proof of Concept** | ERC-2021-PoC
Open: 14-01-2021
Deadlines: 16-03-2021, 17-06-2021, 20-10-2021
Synergy Grants
No Synergy Grant call in 2021 (foreseen again in 2022)

Please note that the dates are subject to the adoption of Horizon Europe and the ERC Work Programme 2021.

European Foundation for the Study of Diabetes (EFSD) and Lilly EXPLORING AND APPLYING NEW STRATEGIES IN DIABETES (EXPAND) Programme

Deadlines: November 02, 2020

Budget: up to 150000,00 EUR

The EFSD/Lilly EXPAND Programme aims to assess with dedicated research projects, potential strategies that could be implemented in Europe and rolled out in low-and middle income countries to favour the improvement of quality of care for all people living with diabetes. We will consider research applications in collaboration with DAC countries - the list can be viewed here.

To achieve the goals and objectives of this programme, EFSD and Lilly invite applications by issuing this “Request for Applications” (RFA). The EFSD/Lilly Programme will accept applications within any area of clinical diabetes research with emphasis on:
- Prevention of diabetes, including lifestyle and educational interventions.
- Diagnosis/management of all forms of diabetes mellitus.
- Diagnosis/prevention of diabetes-related microvascular complications.
- Diagnosis/prevention of diabetes-related macrovascular complications.

The overall goals are to achieve:
- Long-term sustainability of proposed interventions.
- Replicability of proposed projects in other regions/ countries.
- Direct involvement and commitment of local health authorities (co-funding).
- Incorporation of the outcomes in the existing health care system?

European Foundation for the Study of Diabetes (EFSD) and Lilly EXPLORING AND APPLYING NEW STRATEGIES IN DIABETES (EXPAND) Programme

Fondazione Ricerca Fibrosi cistica - Onlus CALL FOR GRANT APPLICATIONS YEAR 2020

Il 15 dicembre di ogni anno viene emanato un bando per la presentazione di progetti di ricerca sulla fibrosi cistica, con aree prioritarie di ricerca definite, entro le quali devono collocarsi i progetti, che si richiede siano orientati, più o meno direttamente, a cure innovative per la malattia. La scadenza, improrogabile, della presentazione dei progetti è al 15 febbraio dell'anno successivo.

Call opening date: December 15, 2020

Budget: up to 130000,00 EUR for a 2 years’ project; up to 70000,00 EUR for an 1 year project.

The Italian Cystic Fibrosis Research Foundation (FFC) funds a limited number of research projects that have the ultimate aim to improve the health status of cystic fibrosis (CF) patients. Research proposals
in which translational objectives are clearly evident will be prioritized. Accordingly, research projects dealing with either clinical studies or pre-clinical studies exploiting animal models of CF are strongly encouraged. Multi-centre applications that combine different expertise in one project will be given a higher priority only if there is convincing evidence that the expected output will be more effective than the sum of individual projects.

**Priority areas**

1. Pathophysiology of the basic defect in cystic fibrosis and pharmacological approaches designed to correct defective CFTR or to compensate for its deficient function.
2. Identification and validation of new and appropriate in vivo and ex vivo assays to predict and monitor the potential efficacy of new therapies finalized to correct the CFTR defect.
3. Lung infection in CF: pathogenetic mechanisms and development of innovative diagnostic and antimicrobial strategies (studies clearly oriented towards possible clinical applications). 
4. Lung inflammation in CF: innovative strategies to reduce the inflammation-based pathology specifically in CF and CF animal models (studies with evident translational potential).
5. Clinical applications in CF prevention, diagnosis, therapy, rehabilitation, care and health organization: clinical trials, with particular regard to phase IV clinical studies (post-marketing), and those to improve the outcomes of lung transplantation in CF; epidemiological studies and systematic reviews.

**Humboldt Research Fellowship for postdoctoral and experienced researchers**

**Selection date:** March, July, November every year. Application should be sent four to eight months before the chosen selection date.

**Budget:** depending on the researcher profile

Humboldt Research Fellowship for postdoctoral and experienced researchers

The Humboldt Research Fellowship for researchers of all nationalities and research areas: We support you – postdoctoral and experienced researchers – with your research in Germany.

Through the Humboldt Research Fellowship, the Alexander von Humboldt Foundation sponsors researchers with above-average qualifications from across the globe. As a fellow, you will benefit from individual support from the Humboldt Foundation and our diverse sponsorship portfolio.

**Postdocs:** Benefit from research sponsorship in Germany at the beginning of your academic career. The Humboldt Research Fellowship for postdoctoral researchers enables you to conduct research in Germany. The monthly fellowship amount is €2,670. Fellowships may last from 6 to 24 months.

**Experienced researchers:** you can still apply for research sponsorship in Germany even if you are already well advanced in your academic career. The Humboldt Research Fellowship for experienced researchers enables you to conduct research in Germany. The fellowship
amount is €3,170. Fellowships may last from 6 to 18 months and can be divided into up to three stays within three years. Link

---

**Fondazione Celiachia Investigator Grant FC 2020**

**Deadline: 12 October 2020, 17:00**

**Budget: 70000,00 EUR/anno**

La Fondazione Celiachia ha indetto il nuovo Bando Investigator Grant FC 2020, destinato a finanziare i migliori Progetti di Ricerca su celiachia, dermatite erpetiforme e sensibilità al frumento non celiaca (NWGS) proposti e condotti da ricercatori senior (Principal Investigator Applicant, PI) con provata esperienza internazionale nel settore.

I Progetti di Ricerca selezionati per il finanziamento saranno condotti dai rispettivi PI presso l’ente di ricerca italiano non-‐profit (pubblico o privato) di appartenenza. **Possono essere presentati Progetti di Ricerca annuali, biennali o triennali, anche multicentrici.**

Il Bando Investigator Grant FC 2020 è un programma di co-‐finanziamento della ricerca scientifica: il PI e il suo istituto di appartenenza partecipano alla realizzazione del Progetto di Ricerca selezionato mediante propri fondi non-‐profit. Link

---

**RADMET, Radionuclide Metrology laboratories (EUFRAT)**

**2020-1-RD- EUFRAT-RADMET**

**Deadline: 15 October 2020**

The Radionuclide Metrology laboratories (RADMET) are equipped with a broad set of instruments used for nuclear decay measurements, determination of related nuclear data and radiological characterisation of samples and materials. The set-ups, many of them unique in their kind, are used to perform high accuracy measurements of a large number of radionuclides in diverse samples ranging from reference materials for environmental monitoring to solutions for primary standardisation of activity. RADMET is among the few laboratories world-wide to provide reference data to the international reference system (SIR) on the 100 most relevant radionuclides. In connection to the measurements the lab is well equipped for preparing sources dedicated for the specific measurements. Access to the research infrastructure is granted on the basis of Access Units. For RADMET, the Access Unit corresponds to a 'Measurement week' for experimental activities, e.g. to perform the necessary measurements to fulfil the objectives of the project.

For each approved experiment, RADMET will offer the best possible measurement conditions according to the specifications of the users and guaranteeing an optimal data output. The JRC may provide a financial or in-kind contribution to support Users to cover their costs of travel and subsistence (T&S)
related to User Stay Days, subject to the availability of funds, personnel and other resources to Users from User Institutions located in an EU Member State or country associated to the Euratom Research Programme (only Switzerland and Ukraine).

---

2020 EDCTP prizes

Deadline: October 29, 2020, at 17.00 CET

Budget: depending on the profile (see below)

EDCTP intends to award four prestigious international prizes dedicated to the promotion of scientific research, improved health and Africa-European collaboration. Prizes will be awarded in a ceremony at the tenth EDCTP Forum which will take place in Maputo, Mozambique, from 17-20 October 2021.

**Scientific Leadership Prize** – €10,000:
Awarded to excellent world-class scientists in sub-Saharan Africa up to 50 years of age working on HIV/AIDS, tuberculosis, malaria and neglected infectious diseases (NIDS) in the scope of the EDCTP2 programme.

**Outstanding Female Scientist Prize** – €20,000:
Awarded to excellent world-class female scientists in sub-Saharan Africa and working in the scope of the EDCTP2 programme.

**Outstanding Research Team Prize** – €50,000:
Awarded to outstanding research teams in sub-Saharan Africa and Europe working on HIV/AIDS, tuberculosis, malaria and neglected infectious diseases (NIDS) in the scope of the EDCTP2 programme.

**Dr Pascoal Mocumbi Prize** – €50,000:
This prize is named after Dr Pascoal Mocumbi, the first High Representative of EDCTP A, in special recognition of his significant contribution to the development of EDCTP as an international collaborative research partnership. It is to be awarded to senior scientists, policy-makers or advocates for health and research, from anywhere in the world.

---

**HORIZON PRIZES**

**EIC Horizon Prize for 'Early Warning for Epidemics'**

H2020-Epidemics-EICPrize-2020

**Letter of Interest: October 31, 2020**

**Submission Deadline: February 16, 2021**

**Budget: up to 5000000,00 EUR**

The challenge is to develop a scalable, reliable and cost-effective early warning system prototype to forecast and monitor vector-borne diseases in order to contribute to the prevention of outbreaks mitigating their impact on local, regional and global scales and providing support to existing elimination efforts.

According to the World Health Organisation (WHO), vector-borne diseases such as malaria, Zika, dengue or yellow fever cause more than 1 million deaths globally each year. Vectors are living organisms that can transmit infectious
diseases between humans or from animals to humans. Vector-borne diseases are a global threat to public health and can have far-reaching economic and social impacts. Climate and environmental phenomena contribute to creating the necessary conditions for these kinds of diseases to thrive. Variables such as rainfall, temperature and humidity affect the number and survival rate of mosquitoes and other vectors of diseases.

The 2030 Agenda for Sustainable Development, in the context of its Sustainable Development Goal 3 "Ensure healthy lives and promote well-being for all at all ages", aims to end the epidemics of malaria and neglected tropical diseases (amongst others) by 2030. It calls for strengthening the capacity of all countries, in particular developing countries, for early warning, risk reduction and management of national and global health risks.

The Earth Observation domain is changing with increasing amounts of data being generated from space-borne, air-borne, in-situ and citizen observatories. Effective management of big data in this domain shall be an essential element in improving the ‘early warning’ capabilities of any system which aims to mitigate epidemics related to vector-borne diseases. The full potential of combining all the available data is not yet harnessed and innovative solutions are needed to enable the system’s wider use and exploitation in this context. Such solutions would not only help to improve the ‘preparedness’ and response related to vector-borne disease outbreaks, but also foster the creation of a digital solution marketplace in the domain of environmental and climate health risks.

The specific rules of the contest are published in the H2020 Participant Portal by the European Commission, which will directly launch and manage the contest and award the prize based on the judgement of independent experts.

Expected Impact:
- A reliable, cost-effective and scalable early warning system prototype to forecast and monitor vector-borne diseases, which should encompass innovative technological solutions integrating big data derived from different sources (e.g. space-borne, airborne, in-situ and citizen observations) in Earth observation domain, including climate data, vector-related modelling, meteorology, and geo-located information related to vector borne disease outbreaks and behaviour. These should be interoperable with public health data and other socio-economic data.
- Demonstration of the prototype at local level, taking into account any relevant societal factors in the chosen geographical area. It should be compatible for use with data coming from existing multi-disciplinary networks comprising health, humanitarian aid and emergency management actors, in order to leverage data and information from these networks, as well as to showcase the operational potential and added value of the solution.

Link